AOST2032: A Feasibility and Randomized Phase 2/3 Study of the VEFGR2/MET Inhibitor Cabozantinib in Combination with Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma (CTMS# 23-0054)
Lay Description
Category
- Cancers and Other Neoplasms
- Muscle, Bone and Cartilage
- IRB Number
- 20230299HU
- NCT Number
- ct.gov registration not required
- Open to Enrollment
- Yes
Eligibility
- Eligible Ages
- Eligible Genders
- Accepts Healthy Volunteers
Inclusion Criteria
Exclusion Criteria
Study Design
Arm Groups
Study Contact
Virginia Diaz
(210) 562-9149
diazvr@uthscsa.edu
Jaclyn Hung
+1 (210) 450-5358
hungj@uthscsa.edu
Virginia Diaz
(210) 562-9149
diazvr@uthscsa.edu
Jaclyn Hung
+1 (210) 450-5358
hungj@uthscsa.edu
Principal Investigator
Anne-Marie Langevin